Sep 28, 2026 06:01AM
Sep 28, 2026 06:00AM
Sep 24, 2026 06:00AM
Sep 24, 2026 06:00AM
Sep 17, 2026 02:51AM
Sep 8, 2026 06:00AM
Jul 15, 2026 08:03AM MediciNova reaches 200-patient enrollment in NIH-funded ALS study
Jul 15, 2026 08:00AM
Jun 30, 2026 08:01AM
Jun 30, 2026 08:00AM
Jun 8, 2026 08:00AM
Jun 8, 2026 08:00AM
May 26, 2026 07:00PM
Apr 27, 2026 07:00PM New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
Mar 16, 2026 07:00AM
Jan 29, 2026 06:01PM
Jan 29, 2026 06:00PM
Jan 6, 2026 09:00AM
Dec 18, 2025 06:01AM
Dec 18, 2025 06:00AM
Dec 8, 2025 06:00AM MediciNova completes enrollment in ALS drug trial with 234 patients
Dec 8, 2025 06:00AM
Nov 18, 2025 06:01AM
Nov 18, 2025 06:00AM
Nov 6, 2025 06:00PM
Nov 4, 2025 07:00AM
Oct 30, 2025 07:00PM
Oct 6, 2025 08:00AM MediciNova to Present at the LD Micro Main Event XIX Investor Conference
Sep 22, 2025 08:03AM
Sep 22, 2025 08:00AM
Sep 16, 2025 08:00AM
Sep 8, 2025 09:02AM
Sep 8, 2025 09:00AM
Sep 3, 2025 07:00AM
Aug 26, 2025 07:00PM MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
Jul 31, 2025 07:31PM
Jul 31, 2025 07:30PM
Jul 24, 2025 06:01AM
Jul 24, 2025 06:00AM
Apr 14, 2025 07:00PM
Apr 8, 2025 07:00PM
Dec 5, 2024 06:00PM MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
Nov 19, 2024 09:02AM
Nov 19, 2024 09:00AM
Nov 14, 2024 06:00PM
Nov 11, 2024 06:00PM
Oct 23, 2024 07:00PM
Sep 30, 2024 09:00AM
Sep 9, 2024 07:00PM MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
Sep 3, 2024 07:00PM

332,175 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All